Phoenix Bio

研究発表

研究発表

Hepatitis B Virus Therapeutic Agent ARB-1740 Has Inhibitory Effect on Hepatitis Delta Virus in a New Dually-Infected Humanized Mouse Model

    Ye, X. Tateno, C. Thi, E. P. Kakuni, M. Snead, N. M. Ishida, Y. Barnard, T. R. Sofia, M. Shimada, T. Lee, A. C. H.

    ACS Infect Dis. 2018 Nov 8. doi: 10.1021/acsinfecdis.8b00192.

    ARB-1740, a RNA Interference Therapeutic for Chronic Hepatitis B Infection

      Thi, E. P. Dhillon, A. P. Ardzinski, A. Bidirici-Ertekin, L. Cobarrubias, K. D. Cuconati, A. Kondratowicz, A. S. Kwak, K. Li, A. H. L. Miller, A. Pasetka, C. Pei, L.Phelps, J. R. Snead, N. M. Wang, X. Ye, X. Sofia, M. J. Lee, A. C. H.

      ACS Infect Dis. 2018 Nov 19. doi: 10.1021/acsinfecdis.8b00191.

      Endoplasmic reticulum-mediated induction of interleukin-8 occurs by hepatitis B virus infection and contributes to suppression of interferon responsiveness in human hepatocytes

        Tsuge, M. Hiraga, N. Zhang, Y. Yamashita, M.  Sato, O. Oka, N. Shiraishi, K. Izaki, Y. Makokha, G. N. Uchida, T. Kurihara, M. Nomura, M. Tsushima, K. Nakahara, T. Murakami, E. Abe-Chayama, H. Kawaoka, T. Miki, D. Imamura, M. Kawakami, Y. Aikata, H. Ochi, H. Hayes, C. N. Fujita, T. Chayama, K.

        Virology. 2018 Sep 18;525:48-61. doi: 10.1016/j.virol.2018.08.020.

        CTL-associated and NK cell-associated immune responses induce different HBV DNA reduction patterns in chronic hepatitis B patients

          Nomura, M. Tsuge, M. Uchida, T. Hiraga, N. Kurihara, M. Tsushima, K. Fujino, H. Nakahara, T. Murakami, E. Abe-Chayama, H. Kawaoka, T. Miki, D. Hiramatsu, A. Imamura, M. Kawakami, Y. Aikata, H. Ochi, H. Zhang, Y. Makokha, G. N. Hayes, C. N. Tanaka, S. Chayama, K.

          J Viral Hepat. 2018 Jul 11. doi: 10.1111/jvh.12970.

          Inhibitory effect of fasiglifam on hepatitis B virus infections through suppression of the sodium taurocholate cotransporting polypeptide

            Nio, Y. Akahori, Y. Okamura, H. Watashi, K. Wakita, T. Hijikata, M.

            Biochem Biophys Res Commun. 2018 Jun 27;501(3):820-825.

            Inhibitory effect of silibinin on hepatitis B virus entry

              Umetsu, T. Inoue, J. Kogure, T. Kakazu, E. Ninomiya, M. Iwata, T. Takai, S. Nakamura, T.Sano, A. Shimosegawa, T.

              Biochem Biophys Rep. 2018 Mar 31;14:20-25.

              Characterization of HBV integration patterns and timing in liver cancer and HBV-infected livers

                Furuta, M. Tanaka, H. Shiraishi, Y. Unida, T. mamura, M. Fujimoto, A. Fujita, M. Sasaki-Oku, A. Maejima, K. Nakano, K. Kawakami, Y. Arihiro, K. Aikata, H. Ueno, M. Hayami, S. Ariizumi, S. I. Yamamoto, M. Gotoh, K. Ohdan, H. Yamaue, H. Miyano, S. Chayama, K. Nakagawa, H.

                Oncotarget. 2018 May 18;9(38):25075-25088.

                Rosmarinic acid is a novel inhibitor for Hepatitis B virus replication targeting viral epsilon RNA-polymerase interaction

                  Tsukamoto, Y. Ikeda, S. Uwai, K. Taguchi, R. Chayama, K. Sakaguchi, T. Narita, R. Yao, W. L. Takeuchi, F. Otakaki, Y. Watashi, K. Wakita, T. Kato, H. Fujita, T.

                  PLoS One. 2018 May 21;13(5):e0197664.

                  Identifying and Characterizing Interplay between Hepatitis B Virus X Protein and Smc5/6

                    Livingston, C. M. Ramakrishnan, D. Strubin, M. Fletcher, S. P. Beran, R. K.

                    Viruses. 2017 Apr 3;9(4). pii: E69. doi: 10.3390/v9040069.

                    Acute HBV infection in humanized chimeric mice has multiphasic viral kinetics

                      Ishida, Y. Chung, T. L. Imamura, M. Hiraga, N. Sen, S. Yokomichi, H. Tateno, C. Canini, L. Perelson, A. S. Uprichard, S. L. Dahari, H. Chayama, K.

                      Hepatology. 2018 Mar 23. doi: 10.1002/hep.29891.

                      Investigating the hepatitis B virus life cycle using engineered reporter hepatitis B viruses

                        Nishitsuji, H. Harada, K. Ujino, S. Zhang, J. Kohara, M. Sugiyama, M. Mizokami, M. Shimotohno, K.

                        Cancer Sci. 2018 Jan;109(1):241-249.

                        A Novel Orally Available Small Molecule That Inhibits Hepatitis B Virus Expression

                          Mueller, H. Wildum, S. Luangsay, S. Walther, J. Lopez, A. Tropberger, P. Ottaviani, G. Lu, W. John Parrott, N. Zhang, J. D. Schmucki, R. Racek, T. Hoflack, J. C. Kueng, E. Point, F. Zhou, X. Steiner, G. Lutgehetmann, M. Rapp, G. Volz, T. Dandri, M. Yang, S. Young, J. A. T. Javanbakht, H.

                          J Hepatol. 2017 Oct 24. pii: S0168-8278(17)32393-0. doi: 10.1016/j.jhep.2017.10.014.

                          Efficacy of NVR 3-778, Alone and in Combination With Pegylated Interferon, vs Entecavir in uPA/SCID Mice With Humanized Livers and HBV Infection

                            Klumpp, K. Shimada, T. Allweiss, L. Volz, T. Lutgehetmann, M. Hartman, G. Flores, O. A. Lam, A. M. Dandri, M.

                            Gastroenterology. 2017 Oct 24. pii: S0016-5085(17)36276-5. doi: 10.1053/j.gastro.2017.10.017.

                            Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus

                              Sato, Y. Matsui, H. Yamamoto, N. Sato, R. Munakata, T. Kohara, M. Harashima, H.

                              J Control Release. 2017 Oct 3;266:216-225. doi: 10.1016/j.jconrel.2017.09.044.

                              Hepatitis B virus evades innate immunity of hepatocytes but activates cytokine production by macrophages

                                Cheng, X. Xia, Y. Serti, E. Block, P. D. Chung, M. Chayama, K. Rehermann, B. Liang, T. J.

                                Hepatology. 2017 Jun 30. doi: 10.1002/hep.29348.

                                Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus

                                  Tsuge, M. Uchida, T. Hiraga, N. Kan, H. Makokha, G. N. Abe-Chayama, H. Miki, D. Imamura, M. Ochi, H. Hayes, C. N. Shimozono, R. Iwamura, T.Narumi, H. Suzuki, T  Kainoh, M. Taniguchi, T.

                                  Antimicrob Agents Chemother. 2017 May 24;61(6).

                                  The Smc5/6 Complex Restricts HBV when Localized to ND10 without Inducing an Innate Immune Response and Is Counteracted by the HBV X Protein Shortly after Infection

                                    Niu, C. Livingston, C. M. Li, L. Beran, R. K. Daffis, S. Ramakrishnan, D. Burdette, D. Peiser, L. Salas, E. Ramos, H. Yu, M. Cheng, G. Strubin, M. Delaney Iv, W. E. Fletcher, S. P.

                                    PLoS One. 2017 Jan 17;12(1):e0169648.

                                    Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor

                                      Decorsiere, A. Mueller, H. van Breugel, P. C. Abdul, F. Gerossier, L. Beran, R. K. Livingston, C. M. Niu, C. Fletcher, S. P. Hantz, O. Strubin, M.

                                      Nature. 2016 Mar 17;531(7594):386-9. doi: 10.1038/nature17170.

                                      Persistent Loss of HBV Markers in Serum without Cellular Immunity by Combination of PEG-IFN Plus ETV Therapy in Humanized Mice

                                        Uchida, T. Imamura, M. Hayes, C. N. Hiraga, N. Kan, H. Tsuge, M. Abe-Chayama, H. Zhang, Y. Makokha, G. N. Aikata, H. Miki, D. Ochi, H. Ishida, Y. Tateno, C. Chayama, K.

                                        Antimicrob Agents Chemother. 2017 Jul 10. pii: AAC.00725-17. doi: 10.1128/AAC.00725-17

                                        Transmission of HBV DNA Mediated by Ceramide-Triggered Extracellular Vesicles

                                          Sanada,Takahiro1,*  Hirata, Yuichi1,* Naito, Yutaka 2,  Yamamoto,Naoki1,  Kikkawa, Yoshiaki3, Ishida, Yuji 4,  Yamasaki,Chihiro 4,  Tateno, Chise 4,  Ochiya, Takahiro 2 and  Kohara, Michinori 1

                                          Cell Mol Gastroenterol Hepatol. 2016 Oct 24;3(2):272-283.